Acadia Pharma (ACAD) Tops Q1 EPS by 13c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.60 +2.31%
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.11, $0.13 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $244.32 million versus the consensus estimate of $239.55 million.
GUIDANCE:
Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.06 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
